Advisor Consultant Network’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Advisor Consultant Network’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$1.25M	Buy	+18,820	New	+$1.16M	0.18%	102

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Advisor Consultant Network's XBI Position: Q3 2016 in Review

Advisor Consultant Network opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2016: 18,820 shares worth $1.25M. The stake represents 0.18% of the portfolio and ranks #102 among its holdings.

228 funds tracked by Wall St. Rank hold XBI as of Q3 2016.

Advisor Consultant Network held 18,820 shares of State Street SPDR S&P Biotech ETF worth $1.25M as of Q3 2016.
State Street SPDR S&P Biotech ETF was a new Advisor Consultant Network position in Q3 2016.
State Street SPDR S&P Biotech ETF made up 0.18% of Advisor Consultant Network's portfolio in Q3 2016, its #102 holding.
228 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2016.

Based on Advisor Consultant Network's 13F filing for Q3 2016, filed 14 Oct 2016.